Skip to main content
Amgen's osteoporosis drug backed by FDA panel
1/17/2019

An FDA advisory committee voted 18-1 in favor of Amgen's Evenity, or romosozumab, as a treatment for postmenopausal women with osteoporosis who are deemed to be at high risk for bone fractures.

Full Story: